 Glucagon-Like Peptides
"Glucagon-Like Peptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.
| Descriptor ID |
D004763
|
| MeSH Number(s) |
D06.472.317.469.500
|
| Concept/Terms |
Glucagon-Like Peptides- Glucagon-Like Peptides
- Glucagon Like Peptides
- Glucagon-Like Polypeptides
- Glucagon Like Polypeptides
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptides".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptides".
This graph shows the total number of publications written about "Glucagon-Like Peptides" by people in this website by year, and whether "Glucagon-Like Peptides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2020 | 2 | 2 | 4 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 4 | 4 | | 2023 | 1 | 2 | 3 | | 2024 | 7 | 3 | 10 | | 2025 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucagon-Like Peptides" by people in Profiles.
-
Ditzenberger GL, Lake JE, Kitch DW, Kantor A, Muthupillai R, Moser C, Belaunzaran-Zamudio PF, Brown TT, Corey K, Landay AL, Avihingsanon A, Sattler FR, Erlandson KM. Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study. Clin Infect Dis. 2025 02 24; 80(2):389-396.
-
Muschler K, Muschalek R, Hoyte C. Characterization of glucagon-like peptide-1 (GLP-1) agonist exposures reported to a single United States poison center. Clin Toxicol (Phila). 2025 Feb; 63(2):133-136.
-
Bonaca MP, Catarig AM, Hansen Y, Houlind K, Ramesh CK, Ludvik B, Nordanstig J, Rasouli N, Sourij H, Verma S. Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes. Eur Heart J Cardiovasc Pharmacother. 2025 Jan 11; 10(8):728-737.
-
Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 Jan; 27(1):1-9.
-
Shah SJ, Sharma K, Borlaug BA, Butler J, Davies M, Kitzman DW, Petrie MC, Verma S, Patel S, Chinnakondepalli KM, Einfeldt MN, Jensen TJ, Rasmussen S, Asleh R, Ben-Gal T, Kosiborod MN. Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials. Eur Heart J. 2024 Sep 14; 45(35):3254-3269.
-
Bjornstad P, Arslanian SA, Hannon TS, Zeitler PS, Francis JL, Curtis AM, Turfanda I, Cox DA. Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study. Diabetes Care. 2024 Sep 01; 47(9):1617-1621.
-
Verma S, Butler J, Borlaug BA, Davies MJ, Kitzman DW, Petrie MC, Shah SJ, Jensen TJ, Rasmussen S, R?nnb?ck C, Merkely B, O'Keefe E, Kosiborod MN. Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart?Failure With Preserved Ejection Fraction: STEP-HFpEF Program. J Am Coll Cardiol. 2024 Oct 22; 84(17):1603-1614.
-
Choy K, Abbitt D, Kovar A, Jones TS, McCallum M, Thomas EA, Saxon DR, Wikiel KJ, Jones EL. Weighing your options-intragastric balloon versus semaglutide. Surg Endosc. 2024 Oct; 38(10):6070-6075.
-
Wagner J. Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes. N Engl J Med. 2024 Jul 25; 391(4):380-381.
-
Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Verma S, Jensen TJ, Einfeldt MN, Liisberg K, Perna E, Sharma K, Ezekowitz JA, Fu M, Melenovsk? V, Ito H, Lelonek M, Kosiborod MN. Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights?From?the?STEP-HFpEF?Program. J Am Coll Cardiol. 2024 Jul 02; 84(1):27-40.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|